Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuyi Liu

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 25, 2010
[A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment.]Zhijie Wang, Jianchun Duan, Qingzhi Guo, et al.
Plant Physiology and Biochemistry : PPB|March 4, 2026
Integrated transcriptomic and metabolomic profiling reveals genotypic differences in UV-B radiation tolerance mechanisms in Elymus sibiricus LFei Zhang, Meixiu Chen, Xuyi Liu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 24, 2011
[Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer]Meina Wu, Yuyan Wang, Tongtong An, et al.
Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland ChinaYi-Long Wu, Da-Tong Chu, Baohui Han, et al.
Journal of Medicinal Chemistry|June 28, 2021
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell LymphomaXuewu Liang, Chenxia Sun, Chunpu Li, et al.
International Journal of Nanomedicine|November 18, 2024
A Multifunctional Low-Temperature Photothermal Nanomedicine for Melanoma Treatment via the Oxidative Stress Pathway TherapyDou Zhang, Xuyi Liu, Xiong Li, et al.
Frontiers in Microbiology|July 14, 2022
Microbial Community Analysis in Sichuan South-road Dark Tea Piled Center at Pile-Fermentation Metaphase and Insight Into Organoleptic Quality Development Mediated by <i>Aspergillus niger</i> M10Yao Zou, Ying Zhang, Yun Tian, et al.
International Journal of Nanomedicine|September 3, 2025
A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR InhibitionGuanming Jiang, Xuyi Liu, Dou Zhang, et al.
Thoracic Cancer|January 15, 2016
Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitorsZhigang Wei, Tongtong An, Zhijie Wang, et al.
Journal of Medicinal Chemistry|February 15, 2021
Discovery of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid TumorsXuewu Liang, Shuai Tang, Xuyi Liu, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|August 25, 2010
[A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment.]Zhijie Wang, Jianchun Duan, Qingzhi Guo, et al.
Plant Physiology and Biochemistry : PPB|March 4, 2026
Integrated transcriptomic and metabolomic profiling reveals genotypic differences in UV-B radiation tolerance mechanisms in Elymus sibiricus LFei Zhang, Meixiu Chen, Xuyi Liu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 24, 2011
[Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer]Meina Wu, Yuyan Wang, Tongtong An, et al.
Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland ChinaYi-Long Wu, Da-Tong Chu, Baohui Han, et al.
Journal of Medicinal Chemistry|June 28, 2021
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell LymphomaXuewu Liang, Chenxia Sun, Chunpu Li, et al.
International Journal of Nanomedicine|November 18, 2024
A Multifunctional Low-Temperature Photothermal Nanomedicine for Melanoma Treatment via the Oxidative Stress Pathway TherapyDou Zhang, Xuyi Liu, Xiong Li, et al.
Frontiers in Microbiology|July 14, 2022
Microbial Community Analysis in Sichuan South-road Dark Tea Piled Center at Pile-Fermentation Metaphase and Insight Into Organoleptic Quality Development Mediated by <i>Aspergillus niger</i> M10Yao Zou, Ying Zhang, Yun Tian, et al.
International Journal of Nanomedicine|September 3, 2025
A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR InhibitionGuanming Jiang, Xuyi Liu, Dou Zhang, et al.
Thoracic Cancer|January 15, 2016
Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitorsZhigang Wei, Tongtong An, Zhijie Wang, et al.
Journal of Medicinal Chemistry|February 15, 2021
Discovery of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid TumorsXuewu Liang, Shuai Tang, Xuyi Liu, et al.
Pageof 5